Chemerin/chemR23 association with endothelial-mesenchymal transition in diabetic nephropathy

International Journal of Clinical and Experimental Pathology

Volumn 10, Issue 7, 2017, Pages 7408-7416

  Wang, Xiaoyang ^a   Guo, Jia ^a   Wu, Qiujie ^a   Niu, Cong ^a   Cheng, Genyang ^a   Liu, Dong ^a   Liu, Zhangsuo ^a   Zhao, Zhanzheng ^a   Xiao, Jing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Chemerin; Diabetic nephropathy; Endothelial mesenchymal transition

Indexed keywords

EID: 85026397589     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS and Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-2539.
2. Ng KP, Jain P, Gill PS, Heer G, Townend JN, Freemantle N, Greenfield S and McManus RJ. Results and lessons from the spironolactone to prevent cardiovascular events in early stage chronic kidney disease (STOP-CKD) randomised controlled trial. BMJ Open 2016; 6: e010519.
3. USRDS N. Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health; 2010.
4. Aghadavod E, Khodadadi S, Baradaran A, Nasri P, Bahmani M and Rafieian-Kopaei M. Role of oxidative stress and inflammatory factors in diabetic kidney disease. Iran J Kidney Dis 2016; 10: 337-343.
5. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S and Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-961.
6. Li J, Qu X and Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol 2009; 175: 1380-1388.
7. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M and Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-2287.
8. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, Ishigaki Y, Kitada M, Srivastava SP and Koya D. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014; 63: 2120-2131.
9. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brezillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M and Communi D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977-985.
10. Lin S, Teng J, Li J, Sun F, Yuan D and Chang J. Association of chemerin and vascular endothelial growth factor (VEGF) with diabetic nephropathy. Med Sci Monit 2016; 22: 3209-3214.
11. Yu QX, Zhang H, Xu WH, Hao F, Liu SL, Bai MM, Mu JW and Zhang HJ. Effect of irbesartan on chemerin in the renal tissues of diabetic rats. Kidney Blood Press Res 2015; 40: 467-477.
12. Hu W and Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res Clin Pract 2011; 91: 159-163.
13. Salama FE, Anass QA, Abdelrahman AA and Saeed EB. Chemerin: a biomarker for cardiovascular disease in diabetic chronic kidney disease patients. Saudi J Kidney Dis Transpl 2016; 27: 977-984.
14. He J, Xu Y, Koya D and Kanasaki K. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol 2013; 17: 488-497.
15. Phanish MK, Winn SK and Dockrell ME. Connective tissue growth factor-(CTGF, CCN2)-a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 2010; 114: e83-92.
16. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S and Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007; 282: 28175-28188.
17. Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M and Chandraratna RA. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 1997; 109: 91-95.
18. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, Mahaney MC, Rainwater DL, VandeBerg JL, MacCluer JW, Collier G, Blangero J, Walder K and Jowett JB. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009; 94: 3085-3088.
19. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K and Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687-4694.
20. De Palma G, Castellano G, Del Prete A, Sozzani S, Fiore N, Loverre A, Parmentier M, Gesualdo L, Grandaliano G and Schena FP. The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney Int 2011; 79: 1228-1235.
21. Li J and Bertram JF. Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis. Nephrology (Carlton) 2010; 15: 507-512.
22. Pfau D, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M and Fasshauer M. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2010; 33: 171-173.
23. Willis BC, duBois RM and Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 2006; 3: 377-382.